Insulin Delivery Devices Market 2018 Key Players – Eli Lilly, Sanofi, Novo Nordisk, Beckton and Dickenson, Roche, Medtronic, Insulet Corporation and Ypsomed

Insulin Delivery Devices Market size will exceed USD 19 billion by 2024; as per a new research report by Global Market Insights, Inc.
Growing prevalence of diabetes coupled increasing awareness about diabetes management and insulin delivery devices are the preliminary factors driving the global insulin delivery devices market.
Product developments and introduction of new products in under-addressed geographical markets should propel industry growth in coming years. Moreover, initiatives by public sectors will also contribute to market expansion during the forecast period. Demand for minimally invasive delivery systems has been fueling the market growth and will continue to drive growth during projection years.

High cost of insulin and certain delivery devices should continue hampering industry growth across the globe, especially in developing regions. Inadequate awareness about various insulin delivery methods further restrains business growth.
Insulin syringes market is forecast to grow with a modest CAGR of over 5%. More efficient and convenient alternatives to syringes will slowly but steadily replace the same, as the market expands.

Request sample copy of this report @ https://www.gminsights.com/request-sample/detail/1649

Insulin pumps market is estimated to experience lucrative growth during the forecast timeframe. In fact, it should grow with fastest CAGR of over 7% in coming 5-6 years, making it second most preferred device in the delivery devices gamut.

U.S. insulin delivery devices market held almost 40% of global market in 2017, owing to high diabetes prevalence, product technological advancements and adoption. During the foreseeable future, industry should grow with low-to-moderate rate because of entering into late market growth phase.

Europe insulin delivery devices market was valued at USD 3 billion in 2017 and it expected to witness more than 5% CAGR from 2018 to 2024. High cost of insulin pumps and insulin pens is driving the insulin delivery devices; however, adoption of pumps is anticipated to surge in near future. Germany is the largest market places in Europe, accounting for nearly 30% share of total market.

Large diabetic population in emerging economies such as China and India will serve as potential consumer base in coming years. China insulin delivery devices market is most likely to be the fastest growing regional market in the world during the projection years. With diabetic population mounting to over 100 million and improving health care in the nation, the market is forecast to grow with exponential rate.

Make Inquiry about this report @ https://www.gminsights.com/inquiry-before-buying/1649

Some of the notable industry players are Sanofi, Ely Lilly, Novo Nordisk, Medtronic, Becton and Dickenson, Roche, Insulet Corporation, Ypsomed. Big established companies hold more than 70% share in total market. Small and medium players are shaping up but face tough competition from dominating counterparts. Technological novel products, geographical product launches and mergers and acquisitions are major strategies practiced by companies to expand their business and foothold in industry.

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com

This release was published on openPR.